Company Monitoring Page for AstraZeneca

latest headlines for company on cafepharma

Bristol, AstraZeneca withdraw diabetes drug in Germany, the day after it was endorsed by an FDA panel
Yahoo/Reuters
Fri, 12/13/13 - 10:43 am
Tags:
Germany, diabetes, AstraZeneca, Dapagliflozin, Bristol-Myers Squibb
FDA panel throws dirt on Bristol-Myers' orphan drug metreleptin
Fierce Biotech
Thu, 12/12/13 - 04:15 pm
Tags:
FDA, advisory panels, Bristol-Myers Squibb, metreleptin, AstraZeneca, partial lipodystrophy
Keep an Eye on AstraZeneca, Avanir, Bristol-Myers Squibb and VIVUS Today
Motley Fool
Thu, 12/12/13 - 11:12 am
Tags:
AstraZeneca, Avair, Bristol-Myers Squibb, Vivus, metreleptin, Nuedexta, Avanafil, Sanofi
Stomach acid drugs may increase vitamin deficiency risk
Reuters
Wed, 12/11/13 - 12:11 pm
Tags:
PPIs, H2RAs, Prevacid, Prilosec, Nexium, Tagamet, Zantac, GSK, Boehringer Ingelheim, P&G, AstraZeneca, Takeda
FDA staff cautious on AstraZeneca, Bristol diabetes drug
Yahoo/Reuters
Tue, 12/10/13 - 09:21 am
Tags:
FDA, AstraZeneca, Bristol-Myers Squibb, Dapagliflozin, diabetes
AstraZeneca is first to win EU approval for an inhaled 4-in-1 flu vaccine
Fierce Pharma
Fri, 12/6/13 - 11:57 am
Tags:
vaccines, Europe, Flu, flu vaccines, AstraZeneca, Fluenz Tetra
Pfizer And GlaxoSmithKline: Aiming For Melanoma Cure Supremacy
Seeking Alpha
Thu, 12/5/13 - 06:43 pm
Tags:
Pfizer, GSK, melanoma, Bristol-Myers Squibb, AstraZeneca, Daiichi Sankyo, Novartis, Yervoy, palbociclib, Mekinist, Zelboraf
AstraZeneca Eyes Forest Labs as Shares Rise
Motley Fool
Thu, 12/5/13 - 08:28 am
Tags:
Forest Labs, AstraZeneca, M&A
5 Blockbuster Drugs Going Off Patent in 2014
Motley Fool
Wed, 12/4/13 - 08:38 am
Tags:
patents, Eli Lilly, Evista, Teva, Copaxone, Novartis, Exforge, Sandostatin LAR, Nexium, AstraZeneca
Report: AstraZeneca kicks tires on Forest, eyes multibillion-dollar deal
Fierce Biotech
Tue, 12/3/13 - 07:24 pm
Tags:
M&A, Forest Labs, AstraZeneca
2014 FDA Drug Approval Decision Calendar
TheStreet.com
Wed, 11/27/13 - 08:39 am
Tags:
FDA, drug approvals, GSK, Gilead, Theravance, Auxilium, Amarin, Bristol-Myers Squibb, Biogen Idec, Pozen, Vanda, Chelsea Therapeutics, pSivida, Alimera, United Therapeutics, Biomarin, JNJ, Pharmacyclics, Celgene, MannKind, Santarus, AstraZeneca, Durata Therapeutics, Eli Lilly, Omeros, BioDelivery Sciences, Anacor, Keryx, Cubist Pharmaceuticals, Nektar
AstraZeneca: A Positive Future Awaits This Company
Seeking Alpha
Tue, 11/26/13 - 04:48 pm
Tags:
AstraZeneca, Bristol-Myers Squibb, Xigduo, diabetes, Dapagliflozin
3 Can't-Miss FDA Actions Coming in December
Motley Fool
Tue, 11/26/13 - 04:42 pm
Tags:
FDA, Gilead Sciences, sofosbuvir, Forxiga, AstraZeneca, Bristol-Myers Squibb, GSK, Anoro Ellipta, Theravance
Opportunities in Lung Cancer Therapies
Motley Fool
Sun, 11/24/13 - 12:30 pm
Tags:
lung cancer, non-small cell lung cancer, Avastin, Genentech, Roche, Tarceva, AstraZeneca, Iressa, Alimta, selumetinib, Array Biopharma, CO-1686, Clovis Oncology, AP26113, Ariad Pharmaceuticals
A Few Dozen Here, A Few Dozen There... More Pharma Layoffs
Pharmalot
Wed, 11/20/13 - 12:10 pm
Tags:
layoffs, Actavis, AstraZeneca, Bayer
Keep an Eye on BioMarin, Amgen, Merck, and AstraZeneca Today
Motley Fool
Tue, 11/19/13 - 12:24 pm
Tags:
Biomarin, Amgen, Merck, AstraZeneca
Why AstraZeneca plc Will Be One Of 2013's Winners
Motley Fool
Fri, 11/15/13 - 10:22 am
Tags:
AstraZeneca
AstraZeneca, Generic Drugmakers Face Class Action on Nexium
Bloomberg/Businessweek
Fri, 11/15/13 - 09:36 am
Tags:
generics, Class Action Lawsuit, AstraZeneca, Nexium, Teva
A SWOT Analysis Of AstraZeneca Plc And GlaxoSmithKline plc
Motley Fool
Thu, 11/14/13 - 10:30 am
Tags:
AstraZeneca, GSK
Cholesterol Guideline Changes Double Number on Treatments
Bloomberg
Wed, 11/13/13 - 08:48 am
Tags:
cholesterol, statins, AstraZeneca, Merck, Pfizer

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.